Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) will move to the next stage of redomiciling its shares on the Nasdaq ahead of an ASX de-listing following approval for share scheme meetings and the dispatch of a scheme booklet from the Australian Federal Court.
CEO Joel Latham has previously stated the board’s unanimous decision to redomicile on the Nasdaq is intended to unlock maximum value for its shareholders.
The newly approved scheme meetings will be held on Wednesday November 8, beginning with the share scheme meeting at 10:00am AEST, with the option scheme meeting beginning at the conclusion of the share scheme meeting or 10:30am AEST, whichever is later.
Independent expert conclusions
IHL says an independent expert has concluded that the share scheme is in the best interests of Incannex Healthcare shareholders, and that the option scheme is in the best interests of option holders.
The board unanimously recommends that both shareholders and option holders vote in favour of their respective scheme.
All Incannex shareholders and Incannex option holders are encouraged to vote by attending the relevant scheme meeting in person or by attorney or corporate representative, or alternatively by completing and ensuring the proxy form accompanying the scheme booklet is received by 10:00am (Melbourne time) on Monday November 6, in respect of the share scheme meeting, and 10:30am (Melbourne time) on Monday, November 6, in respect of the option scheme meeting.
The scheme booklet will be sent to share and option holders and will also be made available on Incannex’s website.